Molecular medicine

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Medicinal chemistry #Molecular medicine #Pathology #PCR #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

GENE EXPRESSION as a toxicological screening tool

GENE EXPRESSION as a toxicological screening tool By Dr Bruce Seligmann The use of microarray data in drug development and requirements for FDA audit and approval. Toxicological safety testing of compounds has not yet advanced to the point where measurement of gene expression is being incorporated in the internal decision… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pathology #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Tissue Microarray (TMA) – A step ahead in drug discovery

Tissue Microarray (TMA) - A step ahead in drug discovery By Dr CR Camozzi Estimation of the clinical importance, market size and therapy-related side-effects are key questions in drug development. The ever-rising costs of drug discovery and development ($800-1,500 million for a successful drug research project) together with demonstrated uncertainty… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Patent Law #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

The impact of early ADME profiling on drug discovery and development strategy

The impact of early ADME profiling on drug discovery and development strategy By Dr Jianling Wang and Dr Laszlo Urban The increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, has led to a new strategy… Read More

#Archive

#Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pharmokinetics #RNA #Sequencing

The Case for Multiplex Protein Assays

The Case for Multiplex Protein Assays By Dr Robert Huang and Dr Diem Nguyen Multiplex testing has gained a growing popularity among scientists, mainly due to financial and competitive pressures forcing companies to narrow their targets and validate their leads as quickly as possible. We discuss how multiplex assays can… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Automation / robotics #Biomarkers #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Metabonomics – A generic platform for the investigation of drug toxicity, altered gene function and disease processes

Metabonomics - A generic platform for the investigation of drug toxicity, altered gene function and disease processes By Professor Jeremy K. Nicholson Metabonomics can offer one of the most complete solutions to tackling one of the pharmaceutical industry's biggest problems attrition. This article discusses the scope and uses of metabonomics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pathology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Systems Biology – Precise phenotypic anchoring for drug target identification, validation and biomarker discovery

By Dr Peter C. Johnson and Dr Alan J. Higgins The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade. This article discusses how systems biology can exploit the natural interlinkages between these datastreams and put in place a powerful system… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Chemical engineering #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microfluidics #Molecular medicine #Patent Law #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Tools for Structural Genomics – Accelerating the structure pipeline

Share Share Tweet Email Tools for Structural Genomics - Accelerating the structure pipeline Tools for Structural Genomics - Accelerating the structure pipeline By Dr Lawrence J. DeLucas, Dr Christie G. Brouillette, Dr Kal Ramnarayan and Dr Shankari Mylvaganam The international structural genomics effort has resulted in a number of technological… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology

Making the Most of Drug Discovery Data

Making the Most of Drug Discovery Data By Dr Nick Davies and Dr Tim Peakman Discovery scientists in most pharmaceutical companies are struggling with incompatible legacy systems, a growing volume of data and the imminent advent of a product model that will demand much more of them. Data-driven drug discovery… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Molecular medicine #PCR #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Toxicology

Gene Expression: Analysis and Drug R&D

Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression or expression… Read More

#Archive

#Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #Sequencing #System biology #Systems biology #Theranostics #Therapeutics

Fewer drugs approved, more money spent – Where’s the beef?

Fewer drugs approved, more money spent - Where's the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone's lips. Billions of dollars were being put to work to make targeted medicine a reality... and genomics… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology

Recent advances in mass spectrometry for drug discovery and development

Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical and biological entities. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Protein BIOMARKER Strategies

By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular assays #Drug development #Drug discovery #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #RNA #Screening #Stem cells

The Industrial Evolution of Screening Infrastructure

The Industrial Evolution of Screening Infrastructure By Chris Molloy Industrialisation of screening depends upon the use of a stable,mature infrastructure. According to a recent Boston Consulting Group report, a pharmaceutical company needs to spend 900 million ($810 million) on R&D to bring a product to market. This is almost three… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Cellular assays #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Organic chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #Target validation

Synthetic approaches to rational drug design – A changing landscape

Synthetic approaches to rational drug design - A changing landscape By Dr Shubh Sharma and Dr Carl Spana It is becoming clearer that newer synthetic approaches for rational drug design may hold the promise of taking us closer to industrialising drug discovery while, at the same time, overcoming the bottleneck… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Molecular pathology and the art of drug design

Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

RNA interference – A technology platform for target validation, drug discovery and therapeutic development

RNA interference - A technology platform for target validation, drug discovery and therapeutic development By Dr Krishnarao Appasani In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'. As we advance in the 'functional omics' arena… Read More

#Archive